CN112641816A - Composition containing jerusalem artichoke extract and application of composition in type II diabetes mellitus and complications - Google Patents
Composition containing jerusalem artichoke extract and application of composition in type II diabetes mellitus and complications Download PDFInfo
- Publication number
- CN112641816A CN112641816A CN202011537380.4A CN202011537380A CN112641816A CN 112641816 A CN112641816 A CN 112641816A CN 202011537380 A CN202011537380 A CN 202011537380A CN 112641816 A CN112641816 A CN 112641816A
- Authority
- CN
- China
- Prior art keywords
- jerusalem artichoke
- extract
- composition
- prepared
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000008892 Helianthus tuberosus Species 0.000 title claims abstract description 144
- 235000003230 Helianthus tuberosus Nutrition 0.000 title claims abstract description 142
- 239000000284 extract Substances 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 27
- 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 238000000605 extraction Methods 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 21
- 239000011259 mixed solution Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 18
- 238000002791 soaking Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000741 silica gel Substances 0.000 claims description 13
- 229910002027 silica gel Inorganic materials 0.000 claims description 13
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 abstract description 6
- 239000002699 waste material Substances 0.000 abstract description 6
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 241000700159 Rattus Species 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 208000033808 peripheral neuropathy Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000007830 nerve conduction Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003372 electrophysiological method Methods 0.000 description 2
- 210000003099 femoral nerve Anatomy 0.000 description 2
- 235000021433 fructose syrup Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000014526 Conduction disease Diseases 0.000 description 1
- 244000251987 Coprinus macrorhizus Species 0.000 description 1
- 235000001673 Coprinus macrorhizus Nutrition 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition containing jerusalem artichoke extract and application thereof in type II diabetes mellitus and complications. The invention utilizes the jerusalem artichoke root for the first time and extracts the effective components of the jerusalem artichoke root, thereby avoiding the resource waste of the jerusalem artichoke root, opening up a new way for utilizing the whole substance of the jerusalem artichoke, and really realizing the whole plant utilization of the jerusalem artichoke; after the jerusalem artichoke root extract and the jerusalem artichoke tuber extract are compounded according to a certain proportion, the hypoglycemic capacity can be improved, and the complications of type II diabetes can be effectively treated.
Description
Technical Field
The invention relates to the technical field of jerusalem artichoke diabetes treatment, and in particular relates to a composition containing jerusalem artichoke extract and application of the composition in type II diabetes and complications.
Background
Jerusalem artichoke is a cultivated species capable of forming underground tubers in Helianthus of Compositae (Compositae), also known as ginger, jerusalem artichoke, Coprinus cinereus L, and is a perennial herbaceous plant with a height of 1-3 m, and massive underground tubers and fibrous roots. Jerusalem artichoke is warm in taste, but cold-resistant; wet but drought tolerant; the cultivation method is fertile, barren-resistant, saline-alkali-resistant, and can be used for planting in most areas of China, or cultivating in coastal saline soil and irrigating by using seawater. The above-ground stem leaves and underground tubers of the jerusalem artichoke are excellent feeds, the underground tubers contain rich inulin, can be used as vegetables, can also be used for producing fructose syrup and developing alcohol, and are one of future energy plants. Because of its good biological characteristics and economic value, research on Jerusalem artichoke at home and abroad mainly focuses on food, feed, cultivation, fructose syrup production and ecology.
At present, the overground part of jerusalem artichoke flowers and jerusalem artichoke leaves and the underground part of jerusalem artichoke tubers are widely applied, but the underground part of fibrous roots are not researched and utilized at present and are directly wasted, so that the development and utilization degree of the whole jerusalem artichoke plants is reduced, and the resource waste is caused.
With the change of dietary structure and lifestyle, the incidence of diabetes has increased year by year and has become a public health concern. Diabetic complications are important causes affecting the quality of life of human beings and causing disability and death. The type II diabetes is called adult onset diabetes, mostly occurs after the age of 35-40 years, and accounts for more than 90% of diabetics. At present, a plurality of medicines for treating diabetes appear, and related researches show that the effective components in the jerusalem artichoke tubers have a certain treatment effect on the diabetes, but cannot play a treatment effect on complications of the diabetes.
Complications of diabetes mellitus increase the difficulty of treating diabetes mellitus, with the complication of peripheral neuropathy (DPN), one of the most common and serious complications of diabetes mellitus, and the incidence of DPN in the elderly is as high as over 90%. The pathogenesis of the nerve cell is complex, is related to various factors such as hemodynamics abnormity, micro-vessel damage, vascular ischemia and anoxia, metabolic disorder, reduction of neurotrophic factors and the like, and finally the nerve cell anoxia, nerve fiber degeneration, segmental demyelination and nerve conduction disorder are caused. At present, no medicine capable of treating type II diabetes and peripheral neuropathy complications simultaneously exists, and no research on jerusalem artichoke root extract exists.
Related researches on the application of the jerusalem artichoke root extract in reducing blood sugar and preventing and treating type II diabetes complications do not appear, and related researches on the application of a composition prepared by compounding the jerusalem artichoke root extract and the jerusalem artichoke tuber extract in reducing blood sugar and preventing and treating type II diabetes complications do not appear.
The composition prepared by compounding the jerusalem artichoke root extract and the jerusalem artichoke tuber extract according to a certain proportion has a treatment effect on type II diabetes mellitus and peripheral neuropathy of complications of the type II diabetes mellitus.
Disclosure of Invention
In view of the above prior art, the present invention aims to provide a composition containing Jerusalem artichoke extract and its application in type II diabetes and complications. After the jerusalem artichoke root extract and the jerusalem artichoke tuber extract are compounded according to a certain proportion, the type II diabetes mellitus and the peripheral neuropathy of complications can be effectively treated; the invention utilizes the jerusalem artichoke root for the first time and extracts the effective components of the jerusalem artichoke root, thereby avoiding the resource waste of the jerusalem artichoke root, opening up a new way for utilizing the whole substance of the jerusalem artichoke, and really realizing the whole plant utilization of the jerusalem artichoke; the jerusalem artichoke root extract is applied to the field of the treatment of the type II diabetes and the complications, and the new application of the jerusalem artichoke root extract and the new idea of applying the jerusalem artichoke root extract to the treatment of the type II diabetes and the complications are developed.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect of the invention, a composition is provided comprising 2-5 parts of an extract of Jerusalem artichoke root and 1-2 parts of an extract of Jerusalem artichoke tuber.
Preferably, the jerusalem artichoke root extract is prepared by the following method:
(1) drying and crushing jerusalem artichoke roots to obtain jerusalem artichoke root powder;
(2) soaking Jerusalem artichoke root powder in water, heating and decocting for 2-3 times, separating and collecting decoctions, and mixing to obtain a mixed solution I;
(3) adding an extracting agent into the mixed liquor I prepared in the step (2) for 2-3 times of extraction, and combining the extracted liquor prepared each time to obtain mixed liquor II, wherein the extracting agent is ethyl acetate;
(4) and (4) concentrating and drying the extract liquid prepared in the step (3) to obtain the jerusalem artichoke root extract.
More preferably, in the step (2), the jerusalem artichoke root powder and water are mixed according to a solid-to-liquid ratio of 1 g: (20-30) ml, soaking for 0.5-1h, and decocting for 0.5-1h each time.
More preferably, in the step (3), the volume ratio of the mixed solution I to the extracting agent is 1 (5-6), the extraction time is 1-2h each time, and the extraction temperature is 105-120 ℃.
Preferably, the jerusalem artichoke tuber extract is prepared by the following method:
(1) drying and crushing jerusalem artichoke tubers to obtain jerusalem artichoke tuber powder;
(2) soaking Jerusalem artichoke tuber powder in water, heating and decocting for 2-3 times, separating and collecting decoctions, mixing, and collecting residue;
(3) carrying out ethanol reflux extraction on the filter residue obtained in the step (2), and filtering after extraction to obtain a filtrate;
(4) mixing the filtrate and the decoction to obtain a mixed solution, and concentrating the mixed solution to obtain an extract;
(5) and (3) performing gradient elution on the extract obtained in the step (4) through a silica gel column, and using ethanol and cyclohexane as eluent, wherein the volume ratio of the gradient elution of the ethanol and the cyclohexane is 1:2, 1:4 and 1: 6. 1: 8;
(6) eluting the eluent according to the volume ratio of 1:8, collecting the obtained effective components, and drying to obtain the jerusalem artichoke tuber extract.
More preferably, in the step (3), the ethanol reflux extraction conditions are as follows: mixing Jerusalem artichoke tuber powder according to the solid-liquid ratio of 1 g: (10-15) ml of the extract is added into ethanol with the volume concentration of 70-80 percent, and the reflux extraction is carried out for 1-2h at the temperature of 55-65 ℃.
More preferably, in step (4), the concentration is carried out at 65-75 deg.C and under 15-25kpa until the relative density is 1.3-1.35.
More preferably, in step (5), the flow rate of the eluate is controlled to be 1 to 1.2 bed volumes per hour.
More preferably, in the step (5), the weight ratio of the extract to the silica gel is 1 (10-15), and the specification of the silica gel is 200 meshes.
In a second aspect of the present invention, there is provided a use of the above composition in the preparation of a medicament for treating type ii diabetes and complications thereof.
In a third aspect of the present invention, there is provided a medicament for treating type ii diabetes and complications thereof, which comprises the above composition as an active ingredient.
The invention has the beneficial effects that:
1. the invention utilizes the jerusalem artichoke root for the first time and extracts the effective components of the jerusalem artichoke root, thereby avoiding the resource waste of the jerusalem artichoke root, opening up a new way for utilizing the whole substance of the jerusalem artichoke, and really realizing the whole plant utilization of the jerusalem artichoke; the jerusalem artichoke root extract is applied to the field of treatment of type II diabetes and complications, and a new application of the jerusalem artichoke root and a new idea of applying the jerusalem artichoke root extract to the treatment of peripheral neuropathy of the type II diabetes and the complications are developed.
2. After the jerusalem artichoke root extract and the jerusalem artichoke tuber extract are compounded according to a certain proportion, the hypoglycemic capacity can be improved, and the complications of type II diabetes mellitus, particularly peripheral neuropathy caused by type II diabetes mellitus, can be effectively treated.
3. The extract is prepared by taking jerusalem artichoke roots and jerusalem artichoke tubers as raw materials, and the extract has the advantages of wide raw material source, low price, low production cost and simple production process, and is suitable for various mass production.
Detailed Description
It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
As introduced in the background art, the over-ground parts of jerusalem artichoke flowers and jerusalem artichoke leaves and the under-ground parts of jerusalem artichoke tubers are widely used at present, but the fibrous roots of the under-ground parts are not researched and utilized at present and are directly wasted, so that the development and utilization degree of the whole jerusalem artichoke plants is reduced, and the resource waste is caused.
Based on the method, the jerusalem artichoke roots are utilized and the effective components of the jerusalem artichoke roots are extracted by the extraction method, so that the resource waste of the jerusalem artichoke roots is avoided, a new way for utilizing all the substances of the jerusalem artichoke is developed, and the full plant utilization of the jerusalem artichoke is really realized; meanwhile, the jerusalem artichoke root extract and the jerusalem artichoke tuber extract are compounded according to a certain proportion and then are applied to the field of treatment of type II diabetes and peripheral neuropathy of complications, so that the hypoglycemic capacity can be improved, the complications of the type II diabetes can be effectively treated, and the new application of the jerusalem artichoke root is developed.
In order to make the technical solutions of the present application more clearly understood by those skilled in the art, the technical solutions of the present application will be described in detail below with reference to specific embodiments.
The test materials used in the examples and comparative examples of the present invention are conventional in the art and are commercially available.
Example 1:
preparation of extract of Jerusalem artichoke root
(1) Drying and crushing the jerusalem artichoke roots, and sieving the crushed jerusalem artichoke roots with a 50-mesh sieve to obtain jerusalem artichoke root powder;
(2) soaking Jerusalem artichoke root powder in water, heating and decocting for 2 times, separating and collecting decoctions, and mixing to obtain a mixed solution I; the jerusalem artichoke root powder and water are mixed according to the solid-liquid ratio of 1 g: adding 20ml of the mixture, soaking for 0.5h, and decocting for 1h each time;
(3) adding an extracting agent into the mixed liquor I prepared in the step (2) for 2 times of extraction, and combining the extract liquor prepared each time to obtain mixed liquor II, wherein the extracting agent is ethyl acetate; the volume ratio of the mixed solution I to the extracting agent is 1:5, the extraction time is 1h each time, and the extraction temperature is 120 ℃;
(4) and (4) concentrating and drying the extract liquid prepared in the step (3) to obtain the jerusalem artichoke root extract.
Preparation of Jerusalem artichoke tuber extract
(1) Drying and crushing jerusalem artichoke tubers, and sieving the crushed jerusalem artichoke tubers with a 70-mesh sieve to obtain jerusalem artichoke tuber powder;
(2) soaking Jerusalem artichoke tuber powder in water, heating and decocting for 2 times, separating and collecting decoctions, mixing, and collecting residue; the jerusalem artichoke tuber powder and water are mixed according to the solid-to-liquid ratio of 1 g: adding 15ml of the mixture, soaking for 0.5h, and decocting for 1h each time;
(3) carrying out ethanol reflux extraction on the filter residue obtained in the step (2), and filtering after extraction to obtain a filtrate; the ethanol reflux extraction conditions are as follows: mixing Jerusalem artichoke tuber powder according to the solid-liquid ratio of 1 g: adding 10ml of the mixture into 70% ethanol by volume, and performing reflux extraction at 55 ℃ for 2 hours;
(4) mixing the filtrate and the decoction to obtain a mixed solution, and concentrating the mixed solution to obtain an extract; concentrating at 65 deg.C under 25kpa to relative density of 1.3-1.35;
(5) and (3) performing gradient elution on the extract obtained in the step (4) through a silica gel column, and using ethanol and cyclohexane as eluent, wherein the volume ratio of the gradient elution of the ethanol and the cyclohexane is 1:2, 1:4 and 1: 6. 1: 8; the eluent flow rate was controlled at 1 bed volume per hour; the weight ratio of the extract to the silica gel is 1:12, and the specification of the silica gel is 200 meshes;
(6) eluting the eluent according to the volume ratio of 1:8, collecting the obtained effective components, and drying to obtain the jerusalem artichoke tuber extract.
Mixing the extract of Jerusalem artichoke root and tuber at a ratio of 2:1 to obtain the composition.
Example 2:
preparation of extract of Jerusalem artichoke root
(1) Drying and crushing the jerusalem artichoke roots, and sieving the crushed jerusalem artichoke roots with a 60-mesh sieve to obtain jerusalem artichoke root powder;
(2) soaking Jerusalem artichoke root powder in water, heating and decocting for 3 times, separating and collecting decoctions, and mixing to obtain a mixed solution I; the jerusalem artichoke root powder and water are mixed according to the solid-liquid ratio of 1 g: adding 30ml of the mixture, soaking for 1 hour, and decocting for 0.5 hour each time;
(3) adding an extracting agent into the mixed liquor I prepared in the step (2) for extraction for 3 times, and combining the extract liquor prepared each time to obtain mixed liquor II, wherein the extracting agent is ethyl acetate; the volume ratio of the mixed solution I to the extracting agent is 1:6, the extraction time is 2 hours each time, and the extraction temperature is 105 ℃;
(4) and (4) concentrating and drying the extract liquid prepared in the step (3) to obtain the jerusalem artichoke root extract.
Preparation of Jerusalem artichoke tuber extract
(1) Drying and crushing jerusalem artichoke tubers, and sieving the crushed jerusalem artichoke tubers with a 80-mesh sieve to obtain jerusalem artichoke tuber powder;
(2) soaking Jerusalem artichoke tuber powder in water, heating and decocting for 3 times, separating and collecting decoctions, mixing, and collecting residue; the jerusalem artichoke tuber powder and water are mixed according to the solid-to-liquid ratio of 1 g: adding 25ml of the mixture, soaking for 1 hour, and decocting for 0.5 hour each time;
(3) carrying out ethanol reflux extraction on the filter residue obtained in the step (2), and filtering after extraction to obtain a filtrate; the ethanol reflux extraction conditions are as follows: mixing Jerusalem artichoke tuber powder according to the solid-liquid ratio of 1 g: adding 15ml of the mixture into 80% ethanol by volume concentration, and performing reflux extraction for 1h at the temperature of 65 ℃;
(4) mixing the filtrate and the decoction to obtain a mixed solution, and concentrating the mixed solution to obtain an extract; concentrating at 75 deg.C under 15kpa to relative density of 1.3-1.35;
(5) and (3) performing gradient elution on the extract obtained in the step (4) through a silica gel column, and using ethanol and cyclohexane as eluent, wherein the volume ratio of the gradient elution of the ethanol and the cyclohexane is 1:2, 1:4 and 1: 6. 1: 8; the eluent flow rate was controlled at 1.2 bed volumes per hour; the weight ratio of the extract to the silica gel is 1:10, and the specification of the silica gel is 200 meshes;
(6) eluting the eluent according to the volume ratio of 1:8, collecting the obtained effective components, and drying to obtain the jerusalem artichoke tuber extract.
Mixing Jerusalem artichoke root extract and Jerusalem artichoke tuber extract at a ratio of 3:1 to obtain composition.
Example 3: preparation of extract of Jerusalem artichoke root
(1) Drying and crushing the jerusalem artichoke roots, and sieving the crushed jerusalem artichoke roots with a 60-mesh sieve to obtain jerusalem artichoke root powder;
(2) soaking Jerusalem artichoke root powder in water, heating and decocting for 2 times, separating and collecting decoctions, and mixing to obtain a mixed solution I; the jerusalem artichoke root powder and water are mixed according to the solid-liquid ratio of 1 g: adding 25ml of the mixture, soaking for 0.5h, and decocting for 1h each time;
(3) adding an extracting agent into the mixed liquor I prepared in the step (2) for 2 times of extraction, and combining the extract liquor prepared each time to obtain mixed liquor II, wherein the extracting agent is ethyl acetate; the volume ratio of the mixed solution I to the extracting agent is 1:5, the extraction time is 2 hours each time, and the extraction temperature is 110 ℃;
(4) and (4) concentrating and drying the extract liquid prepared in the step (3) to obtain the jerusalem artichoke root extract.
Preparation of Jerusalem artichoke tuber extract
(1) Drying and crushing jerusalem artichoke tubers, and sieving the crushed jerusalem artichoke tubers with a 80-mesh sieve to obtain jerusalem artichoke tuber powder;
(2) soaking Jerusalem artichoke tuber powder in water, heating and decocting for 2 times, separating and collecting decoctions, mixing, and collecting residue; the jerusalem artichoke tuber powder and water are mixed according to the solid-to-liquid ratio of 1 g: adding 20ml of the mixture, soaking for 0.5h, and decocting for 1h each time;
(3) carrying out ethanol reflux extraction on the filter residue obtained in the step (2), and filtering after extraction to obtain a filtrate; the ethanol reflux extraction conditions are as follows: mixing Jerusalem artichoke tuber powder according to the solid-liquid ratio of 1 g: adding 12ml of the mixture into 70% ethanol by volume, and performing reflux extraction at 60 ℃ for 2 hours;
(4) mixing the filtrate and the decoction to obtain a mixed solution, and concentrating the mixed solution to obtain an extract; concentrating at 70 deg.C under 20kpa to relative density of 1.3-1.35;
(5) and (3) performing gradient elution on the extract obtained in the step (4) through a silica gel column, and using ethanol and cyclohexane as eluent, wherein the volume ratio of the gradient elution of the ethanol and the cyclohexane is 1:2, 1:4 and 1: 6. 1: 8; the eluent flow rate was controlled at 1.2 bed volumes per hour; the weight ratio of the extract to the silica gel is 1:15, and the specification of the silica gel is 200 meshes;
(6) eluting the eluent according to the volume ratio of 1:8, collecting the obtained effective components, and drying to obtain the jerusalem artichoke tuber extract.
Mixing the extract of Jerusalem artichoke root and tuber at a ratio of 5:2 to obtain the composition.
The compositions prepared in examples 1 to 3 were subjected to animal experiments to verify the hypoglycemic effect and the effect of treating type II diabetic complications
Animal experiment one: 80 Wistar rats (provided by Shandong province laboratory animal center) with the weight of 180-200 g are subjected to adaptive pre-feeding for 1 week before test; the rats are randomly divided into 4 groups, the number of the rats in each group is the same, 4 groups of rats establish a diabetes model and are divided into a diabetes model control group, an example 1 group, an example 2 group and an example 3 group, the diabetes model is that 60mg/kg of streptozotocin is injected into the abdominal cavity of the rats, the stomach of the diabetes model control group is perfused with 0.9% of physiological saline for 1 time every day for 6 days, the composition prepared in the example 1 group is perfused with 0.5g of composition prepared in the example 1 for 1 time every day for 6 days, the composition prepared in the example 2 group is perfused with 0.5g of composition prepared in the example 2 for 1 time every day for 6 days, and the composition prepared in the example 3 group is perfused with 0.5g of composition prepared in the example 3 for 1 time every day for 6 days. Rats blood glucose measurements were performed on 4 groups of rats after gavage on day 6.
Rat blood glucose measurements were performed by a rapid glucometer: massaging tail veins of the rat, disinfecting with 75% ethanol, collecting 1 drop of blood after drying, making the blood flow out naturally as much as possible, avoiding squeezing, and detecting the glucose concentration in the peripheral venous whole blood with a rapid glucometer.
TABLE 1
As can be seen from the above table, the compositions prepared from the extract of Jerusalem artichoke root and the extract of Jerusalem artichoke tuber according to the invention have obvious hypoglycemic effect.
Animal experiment II: the femoral nerve conduction velocity of rats was measured by electrophysiological method using rats of the diabetes model control group, example 1 group, example 2 group and example 3 group in animal test one. The method for measuring the femoral nerve conduction velocity of the rat by the electrophysiological method is referred to the methodology investigation of measuring the sciatic nerve conduction velocity of the rat, Yaohanmnu, page 18-20, Chinese pharmacy, 2011, No. 22, No. 1.
Using an indirect in vivo assay: the stimulating double-needle electrode is placed at the sciatic nerve efferent part at the sciatic notch on the right side of the rat and the sciatic nerve passing part of the ankle joint on the same side, the first interosseous muscle part of the toe of the rat is recorded by the double-needle electrode, and the reference electrode is placed between the stimulating electrode and the recording electrode and is 1cm away from the recording electrode. The computer records the nerve impulse conduction latency, the measurement is repeated for 8-10 times, the average value is calculated, and the distances between the two stimulation electrodes and the recording electrode on the body surface of the rat are accurately measured respectively. Substituting into a formula: MNCV (m/s) is the distance difference between the two stimulating electrodes and the recording electrode/the difference in latency between the two stimulating electrodes and the recording electrode, and is calculated as shown in table 2.
TABLE 2
As can be seen from the above table, the conduction time of the control group in the diabetes model was significantly lower than that of the groups of example 1, example 2 and example 3. Therefore, the composition prepared by the jerusalem artichoke root extract and the jerusalem artichoke tuber extract can effectively treat peripheral neuropathy caused by type II diabetes.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (10)
1. A composition characterized by: is prepared from 2-5 parts of Jerusalem artichoke root extract and 1-2 parts of Jerusalem artichoke tuber extract.
2. The composition of claim 1, wherein: the jerusalem artichoke root extract is prepared by the following method:
(1) drying and crushing jerusalem artichoke roots to obtain jerusalem artichoke root powder;
(2) soaking Jerusalem artichoke root powder in water, heating and decocting for 2-3 times, separating and collecting decoctions, and mixing to obtain a mixed solution I;
(3) adding an extracting agent into the mixed liquor I prepared in the step (2) for 2-3 times of extraction, and combining the extracted liquor prepared each time to obtain mixed liquor II, wherein the extracting agent is ethyl acetate;
(4) and (4) concentrating and drying the extract liquid prepared in the step (3) to obtain the jerusalem artichoke root extract.
3. The composition as claimed in claim 2, wherein in the step (2), the Jerusalem artichoke root powder and water are mixed according to a solid-to-liquid ratio of 1 g: (20-30) ml, soaking for 0.5-1h, and decocting for 0.5-1h each time.
4. The composition as claimed in claim 2, wherein in step (3), the volume ratio of the mixed solution I to the extractant is 1 (5-6), the extraction time is 1-2h each time, and the extraction temperature is 105-120 ℃.
5. The composition of claim 1, wherein: the jerusalem artichoke tuber extract is prepared by the following method:
(1) drying and crushing jerusalem artichoke tubers to obtain jerusalem artichoke tuber powder;
(2) soaking Jerusalem artichoke tuber powder in water, heating and decocting for 2-3 times, separating and collecting decoctions, mixing, and collecting residue;
(3) carrying out ethanol reflux extraction on the filter residue obtained in the step (2), and filtering after extraction to obtain a filtrate;
(4) mixing the filtrate and the decoction to obtain a mixed solution, and concentrating the mixed solution to obtain an extract;
(5) and (3) performing gradient elution on the extract obtained in the step (4) through a silica gel column, and using ethanol and cyclohexane as eluent, wherein the volume ratio of the gradient elution of the ethanol and the cyclohexane is 1:2, 1:4 and 1: 6. 1: 8;
(6) eluting the eluent according to the volume ratio of 1:8, collecting the obtained effective components, and drying to obtain the jerusalem artichoke tuber extract.
6. The composition of claim 5, wherein: in the step (3), the ethanol reflux extraction conditions are as follows: mixing Jerusalem artichoke tuber powder according to the solid-liquid ratio of 1 g: (10-15) ml of the extract is added into ethanol with the volume concentration of 70-80 percent, and the reflux extraction is carried out for 1-2h at the temperature of 55-65 ℃.
7. The composition of claim 5, wherein: in the step (4), the concentration temperature is 65-75 ℃, the pressure is 15-25kpa, and the concentration is carried out until the relative density is 1.3-1.35.
8. The composition of claim 5, wherein: in step (5), the flow rate of the eluent is controlled to be 1-1.2 bed volumes per hour.
9. Use of a composition according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of type ii diabetes and complications thereof.
10. A medicament for treating type ii diabetes mellitus and complications thereof, which comprises the composition according to any one of claims 1 to 8 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011537380.4A CN112641816A (en) | 2020-12-23 | 2020-12-23 | Composition containing jerusalem artichoke extract and application of composition in type II diabetes mellitus and complications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011537380.4A CN112641816A (en) | 2020-12-23 | 2020-12-23 | Composition containing jerusalem artichoke extract and application of composition in type II diabetes mellitus and complications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112641816A true CN112641816A (en) | 2021-04-13 |
Family
ID=75359493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011537380.4A Pending CN112641816A (en) | 2020-12-23 | 2020-12-23 | Composition containing jerusalem artichoke extract and application of composition in type II diabetes mellitus and complications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112641816A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117820436A (en) * | 2023-03-24 | 2024-04-05 | 广东旺合生物科技有限公司 | Jerusalem artichoke peptide capable of reducing blood sugar, resisting oxidization and protecting kidneys, preparation method and application thereof in great health |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103965377A (en) * | 2014-05-14 | 2014-08-06 | 东南大学 | Method for preparing synanthrin from jerusalem artichoke |
| CN110973166A (en) * | 2019-11-18 | 2020-04-10 | 山东植益源健康科技有限公司 | Application of jerusalem artichoke root extract in preparation of tea caterpillar insecticide |
| CN112136881A (en) * | 2020-09-22 | 2020-12-29 | 山东安谱检测科技有限公司 | Fruit preservative containing jerusalem artichoke extract and preparation method thereof |
-
2020
- 2020-12-23 CN CN202011537380.4A patent/CN112641816A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103965377A (en) * | 2014-05-14 | 2014-08-06 | 东南大学 | Method for preparing synanthrin from jerusalem artichoke |
| CN110973166A (en) * | 2019-11-18 | 2020-04-10 | 山东植益源健康科技有限公司 | Application of jerusalem artichoke root extract in preparation of tea caterpillar insecticide |
| CN112136881A (en) * | 2020-09-22 | 2020-12-29 | 山东安谱检测科技有限公司 | Fruit preservative containing jerusalem artichoke extract and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 何新华等: "菊芋总糖和菊粉提取工艺条件优化", 《食品研究与开发》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117820436A (en) * | 2023-03-24 | 2024-04-05 | 广东旺合生物科技有限公司 | Jerusalem artichoke peptide capable of reducing blood sugar, resisting oxidization and protecting kidneys, preparation method and application thereof in great health |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103750107A (en) | Health-care product with blood glucose reducing function | |
| CN100404525C (en) | Process of extracting dihydromyricitrin from vine tea | |
| CN112641816A (en) | Composition containing jerusalem artichoke extract and application of composition in type II diabetes mellitus and complications | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN106519054A (en) | Radix pseudostellariae homogeneous polysaccharide for promoting insulin secretion of islet cells and use thereof | |
| CN109694805A (en) | A kind of formula and preparation method thereof of the friendly tender tea leaves alcoholic drink mixed with fruit juice of sugar | |
| CN101904907B (en) | Buckwheat extract abundant in inositol and general flavone and preparation method thereof | |
| KR101411531B1 (en) | Containing vanadium and it's way way to the cultivation of rapeseed oil and use it to grown functional composition for diabetes mellitus | |
| CN108077512B (en) | Moringa oleifera leaf blood sugar reducing tea and preparation method thereof | |
| CN109232757B (en) | Walnut leaf polysaccharide extract and application thereof | |
| CN108771690B (en) | A Balanophora japonica L extract with blood sugar or blood lipid reducing effect, and its preparation method and application | |
| CN113663043B (en) | Composition with alpha-glucosidase inhibition effect and preparation method and application thereof | |
| CN105145931A (en) | Hypoglycemic tea and making method thereof | |
| CN101757059B (en) | Method for extracting alpha-glucosidase activity inhibitor from plants | |
| CN105250342B (en) | Ligularia virgaurea extract, preparation method thereof and application thereof in aspect of reducing blood sugar | |
| CN108853184B (en) | Cyclocarya paliurus and lithocarpus polystachyus rehd extract composition | |
| CN108685964B (en) | Application of gerbera piloselloides extract and preparation method of active ingredients of gerbera piloselloides extract | |
| CN102659874A (en) | Extraction method of alpha-glucosidase inhibitor from hot pepper leaves | |
| CN109053451B (en) | Phenol derivative compound extracted from noni ferment, and extraction method and application thereof | |
| CN101647855B (en) | Traditional Chinese medicine preparation for treating diabetic neuropathy and preparation method thereof | |
| CN105250343B (en) | Artemisia sphaerocephala extract, preparation method thereof and application thereof in reducing blood sugar | |
| CN108743658B (en) | Cyclocarya paliurus and walnut leaf extract composition | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN107041926A (en) | A kind of Chinese bush cherry Hu reed tea and its preparation method and application | |
| CN100446800C (en) | Chinese traditional medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210623 Address after: 271000 1 South Lane Street, Da Wen Kong Industrial Park, man Zhuang Town, Daiyue District, Tai'an, Shandong Applicant after: Shandong yidelai Biotechnology Co.,Ltd. Address before: No. 1406, Nanning Jiazhuang village, Yicheng Town, Ningyang County, Tai'an City, Shandong Province Applicant before: Ningyang Ruihong agricultural planting Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210413 |